Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in young children. Protective therapy options are limited. Currently, palivizumab, a monoclonal IgG1 antibody, is the only licensed drug for RSV prophylaxis, although other IgG antibody candidates are bei...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobino, Shamir R., Nederend, Maaike, Reijneveld, J. Frederiek, Augustijn, Daan, Jansen, J. H. Marco, Meeldijk, Jan, Reiding, Karli R., Wuhrer, Manfred, Coenjaerts, Frank E. J., Hack, C. Erik, Bont, Louis J., Leusen, Jeanette H. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939987/
https://www.ncbi.nlm.nih.gov/pubmed/29553863
http://dx.doi.org/10.1080/19420862.2018.1433974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939987/
https://www.ncbi.nlm.nih.gov/pubmed/29553863
http://dx.doi.org/10.1080/19420862.2018.1433974

Ejemplares similares